Dr. Limin Shang, PhD

Director of Pharmacology at Light Chain Bioscience

Speaker

After obtaining a PhD in pharmacology from SUNY Buffalo, NY, Limin worked on pre-clinical disease models for several years at Roswell Park Cancer Institute and Mount Sinai School of Medicine. Since 2009, he joined Novimmune and was involved in the preclinical development of several therapeutic antibody programs in autoimmunity and κλ body bispecific antibody programs in immuno-oncology.

In July 2019, Novimmune has been rebranded as “Light Chain Bioscience – A brand of Novimmune SA. As the director of pharmacology at Light Chain Bioscience, Limin oversees the pharmacological characterization of all bispecific antibody programs.